Current Value
$2.081 Year Return
Current Value
$2.081 Year Return
Yahoo
Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory and reimbursement supportWill assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company’s Consulting Chief Medical Officer. In this part-time role, he will support a range o
Yahoo
Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA)MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-CodeUp to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than 10,000 patients per year in the US.1 From time of onset of dnDSA, 24% of p
Yahoo
January 13-16, 2025, San Francisco, CAIRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43ʳᵈ Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13-16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors. Investors wish
Yahoo
IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number instabi
Yahoo
Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection. Study published in Nephrology Dialysis Transplantation IRVINE, Calif
Yahoo
OncoCyte Corp (OCX) advances in global transplant testing while navigating pre-revenue challenges and competitive market dynamics.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CLLS | 24.35% | $106.70M | -44.98% | 0.00% |
SEG | 23.01% | $336.81M | +2.94% | 0.00% |
TRI | 22.92% | $71.65B | +5.34% | 1.35% |
VHC | 20.68% | $34.61M | +48.01% | 0.00% |
DOCU | 20.53% | $18.10B | +41.77% | 0.00% |
MNOV | 20.24% | $89.75M | +22.00% | 0.00% |
ZM | 20.05% | $23.93B | +13.08% | 0.00% |
HXL | 19.30% | $5.37B | -6.86% | 0.89% |
APT | 19.22% | $60.49M | +9.78% | 0.00% |
CHEF | 18.75% | $2.09B | +74.35% | 0.00% |
ANAB | 18.55% | $482.29M | -32.47% | 0.00% |
XOS | 18.04% | $26.58M | -58.52% | 0.00% |
ATR | 17.85% | $10.39B | +19.33% | 1.10% |
MSGE | 17.81% | $1.74B | +7.41% | 0.00% |
SEAT | 17.64% | $628.67M | -16.58% | 0.00% |
CASI | 17.56% | $35.11M | -45.07% | 0.00% |
DSGX | 17.52% | $9.91B | +33.27% | 0.00% |
ZTS | 17.29% | $74.84B | -11.94% | 1.04% |
ADSK | 17.04% | $62.66B | +17.22% | 0.00% |
IRDM | 16.92% | $3.21B | -24.42% | 1.93% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
REFI | -15.60% | $307.48M | +0.50% | 11.94% |
BIRK | -15.55% | $11.26B | +29.38% | 0.00% |
HSIC | -13.91% | $9.13B | -1.11% | 0.00% |
HUSA | -13.80% | $21.85M | +7.05% | 0.00% |
VSTS | -13.30% | $2.13B | -21.80% | 0.85% |
CENX | -13.25% | $1.92B | +101.80% | 0.00% |
UGI | -12.21% | $6.46B | +36.15% | 4.96% |
PLCE | -12.12% | $132.32M | -52.83% | 0.00% |
BJ | -12.02% | $12.56B | +44.69% | 0.00% |
ALE | -11.68% | $3.80B | +11.94% | 4.29% |
OLLI | -11.66% | $6.55B | +42.92% | 0.00% |
TPR | -11.62% | $16.64B | +94.84% | 1.94% |
MPAA | -11.57% | $142.93M | -22.50% | 0.00% |
CIG.C | -11.44% | $2.25B | +6.01% | 0.00% |
HLN | -11.03% | $41.83B | +8.83% | 1.72% |
SMPL | -11.01% | $3.42B | -18.15% | 0.00% |
BBW | -10.88% | $525.50M | +77.81% | 2.02% |
SPOK | -10.79% | $322.74M | +1.99% | 7.84% |
QD | -10.49% | $392.13M | +33.64% | 0.00% |
KNDI | -10.48% | $100.46M | -54.18% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CRBU | -<0.01% | $138.55M | -70.12% | 0.00% |
GRWG | 0.01% | $88.87M | -37.24% | 0.00% |
RYI | 0.01% | $661.15M | -35.43% | 3.57% |
GMAB | -0.01% | $13.21B | -28.13% | 0.00% |
UAN | -0.02% | $887.21M | +25.88% | 7.93% |
GIC | -0.02% | $954.24M | -34.86% | 3.99% |
X | 0.02% | $8.12B | -24.65% | 0.54% |
ELS | -0.02% | $12.70B | -2.94% | 2.85% |
HLX | -0.02% | $1.38B | -4.91% | 0.00% |
ASND | -0.03% | $7.66B | -2.95% | 0.00% |
MGA | -0.03% | $11.59B | -26.04% | 4.70% |
SEER | 0.03% | $135.03M | +42.24% | 0.00% |
CPSH | -0.03% | $26.29M | -21.65% | 0.00% |
HE | 0.04% | $1.58B | -28.14% | 0.00% |
DEI | 0.04% | $2.93B | +22.21% | 4.31% |
AIFU | 0.04% | $22.14M | -93.74% | 0.00% |
PINS | -0.04% | $20.63B | -17.71% | 0.00% |
MEG | 0.05% | $776.22M | -19.92% | 0.00% |
CHRD | 0.05% | $7.72B | -14.92% | 6.51% |
AES | -0.06% | $8.40B | -30.02% | 5.78% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -13.19% | $195.31M | 0.85% |
DBA | -13.00% | $807.60M | 0.93% |
IBMN | -11.36% | $473.66M | 0.18% |
DBB | -10.54% | $110.86M | 0.77% |
TAIL | -9.34% | $65.49M | 0.59% |
TPMN | -9.11% | $34.33M | 0.65% |
KMLM | -8.99% | $328.91M | 0.9% |
USCI | -8.87% | $204.06M | 1.07% |
PHDG | -8.86% | $114.88M | 0.39% |
CPER | -8.55% | $157.04M | 0.97% |
HYMU | -7.28% | $267.68M | 0.35% |
SOYB | -7.14% | $26.94M | 0.22% |
TOTL | -7.11% | $3.38B | 0.55% |
HIGH | -6.89% | $245.77M | 0.52% |
FTGC | -6.76% | $2.40B | 1.02% |
FMF | -6.74% | $155.24M | 0.95% |
GCC | -6.33% | $134.04M | 0.55% |
COPX | -6.11% | $2.67B | 0.65% |
BCD | -6.11% | $251.15M | 0.3% |
EPU | -5.98% | $73.67M | 0.59% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
INTF | 0.01% | $1.23B | 0.16% |
IBTL | 0.01% | $270.03M | 0.07% |
IEI | 0.02% | $15.37B | 0.15% |
RSPD | 0.02% | $338.27M | 0.4% |
MXI | 0.02% | $208.49M | 0.42% |
IEF | 0.03% | $31.59B | 0.15% |
BSJP | 0.04% | $1.01B | 0.42% |
IBTJ | 0.04% | $478.95M | 0.07% |
UDN | 0.04% | $46.69M | 0.78% |
CGCB | -0.04% | $1.67B | 0.27% |
CTA | -0.04% | $555.39M | 0.76% |
JIRE | 0.04% | $6.60B | 0.24% |
IBMP | -0.05% | $508.81M | 0.18% |
HTAB | 0.06% | $448.46M | 0.39% |
FIXD | 0.07% | $4.48B | 0.65% |
VUSB | 0.07% | $4.47B | 0.1% |
SCHR | -0.07% | $10.10B | 0.03% |
SPEU | 0.08% | $616.51M | 0.07% |
HYMB | 0.09% | $2.81B | 0.35% |
VGK | 0.10% | $16.75B | 0.09% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VRIG | 19.75% | $1.20B | 0.3% |
HYZD | 17.30% | $170.53M | 0.43% |
SPFF | 16.21% | $143.54M | 0.48% |
FLRN | 16.03% | $2.53B | 0.15% |
VRP | 15.95% | $1.90B | 0.5% |
RSPA | 15.84% | $274.39M | 0% |
PFLD | 15.35% | $473.79M | 0.46% |
ICLO | 14.94% | $301.85M | 0.2% |
IHAK | 14.54% | $947.71M | 0.47% |
KRBN | 14.33% | $192.50M | 0.85% |
EPHE | 14.22% | $91.90M | 0.59% |
BUG | 13.71% | $806.16M | 0.5% |
IGV | 13.46% | $9.66B | 0.41% |
ITA | 13.06% | $6.45B | 0.4% |
HYEM | 12.94% | $395.57M | 0.4% |
CIBR | 12.89% | $7.56B | 0.59% |
FLTR | 12.67% | $1.98B | 0.14% |
PPA | 12.39% | $4.77B | 0.57% |
FPE | 12.30% | $5.77B | 0.85% |
PSK | 12.24% | $898.11M | 0.45% |